On Friday May 24th, 2019 Novartis (NYSE: NVS) gained FDA approval of its gene therapy product " Zolgensma® " for spinal muscular atrophy (SMA), originally purchased from AveXis in 2018 for $8.7 … [Read more...] about Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It
Long-Term Play
Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
ADMP Follows Through on Filing A New Drug Application For Tadalafil Sublingual Tablets
Leave a comment and click here to subscribe for MS article alerts and our newsletter! Adamis Pharmaceutical (NASDAQ: ADMP), a speciality pharmaceutical company, upheld its commitment to file a new … [Read more...] about ADMP Follows Through on Filing A New Drug Application For Tadalafil Sublingual Tablets
Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX
leave a comment and click here to sub for MS article alerts and our newsletter Introduction MS noticed some insightful parallels between when Conatus Pharmaceuticals (Nasdaq: CNAT) … [Read more...] about Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX
Ørsted Positioning For A Foothold In U.S. Markets
Ørsted is the leading the market in the UK.Ørsted set out to be an entirely green company 10 years ago.After dominating the UK market, Ørsted is turning to the opportunities in the U.S.Ørsted intends … [Read more...] about Ørsted Positioning For A Foothold In U.S. Markets
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish
You must be logged in to post a comment.